SynOx Therapeutics Receives Fast Track Designation from US FDA for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)

SynOx Therapeutics announced that the US FDA has granted Fast Track Designation to emactuzumab for the treatment of TGCT patients that are not amenable to or who would not benefit from surgery.